HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Odyssey raises more than $300M as biotech goes public

Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. With its IPO now priced, Odyssey is slated to begin trading on the Nasdaq on Friday ...

By Endpoints News · May 8, 2026 · via Endpoints News
Odyssey raises more than $300M as biotech goes public

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News →

Tags
moneyformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Novo Nordisk’s Wegovy pill lifts Q1 and investor confidence
MoneyBriefing
Novo Nordisk’s Wegovy pill lifts Q1 and investor confidence
The oral Wegovy launch brought $355M in its first quarter, helping Novo beat consensus despite insulin softnes…
May 8, 2026
Amgen, AbbVie say IRA negotiations impacted Q1 sales
MoneyEndpoints News ↗
Amgen, AbbVie say IRA negotiations impacted Q1 sales
At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug pr…
May 6, 2026
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio
MoneyFiercePharma ↗
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star hear…
May 5, 2026